Co-Chairs Centrexion Therapeutics & Metys Pharmaceuticals Send Invites to SMi’s 19th Annual Pain Therapeutics
SMi reports: Invitations for conference co-chairs has been released for the upcoming Pain Therapeutics conference in May this year.
London, United Kingdom, March 08, 2019 --(PR.com)-- On the 13th and 14th May 2019 in London, SMi will host the 19th Annual Pain Therapeutics Conference, which will explore the cutting-edge research of novel therapeutic targets in the pipeline of leading pharmaceutical companies and discuss solutions for the challenges of clinical trial design and conduct.
SMi Group is delighted to have Kerrie Brady, Chief Business Officer, Centrexion Therapeutics and Michael Scherz, Founder & CEO, Metys Pharmaceuticals co-chairing the two-day conference.
The co-chairs invite letter mentions:
"It has been a memorable year for the global pain drug development community.
"The first regulatory approvals for CGRP migraine drugs in the US and Europe have ushered in a novel pharmacological strategy for treating and preventing migraine. On the other hand, Nav1.7 inhibitors had significant challenges in their clinical development, as clinical trial results have been less than encouraging.
"The FDA have awarded, for the first time ever, the Breakthrough designation to promising new pain drugs; and the Agency has promised new guidelines that govern the development of novel therapeutics options for the treatment of pain. The US National Institutes of Health have received $500M in additional funding to facilitate the development of new approaches to pain drug development.
"Pain management is a global concern: the European Horizon 2020 'Towards Transatlantic Co-operation in Pain Research' meeting between leading researchers, clinicians, patient groups and government agencies has recommended collaboration priorities for the EU and North America in research on pain and to accelerate access to better and safer pain treatments.
"Clearly, major changes and challenges are afoot in the novel pain therapeutics ecosystem. Will they make a difference in how we develop new analgesic therapies? Will they lead to new treatments for patients?"
The co-chairs for the 19th SMi Group Conference on Pain Therapeutics Conference further explain how the event will discuss new therapies and new clinical trial methodologies will be discussed.
Join the conference for a stimulating series of presentations by leaders in the growing field of novel pain therapeutics.
The co-chairs look forward to welcoming you in London this May.
For further information on the full two-day agenda and speaker line up, visit: http://www.pain-therapeutics.co.uk/PR2
Places can be reserved at http://www.pain-therapeutics.co.uk/PR2
Pain Therapeutics 2019 is proudly sponsored by CHDR, Lotus Clinical Research, MD Biosciences.
There are tailored sponsorship packages available, if you are interested, contact Alia Malick, Director, on +44 (0) 20 827 6168 or email amalick@smi-online.co.uk
For media enquiries, contact Simi Sapal on +44 (0) 20 7827 6000 or ssapal@smi-online.co.uk
Pain Therapeutics 2019
13 – 14 May 2019
Copthorne Tara Hotel, London, UK
http://www.pain-therapeutics.co.uk/PR2
Follow us @SMiPharm
#SMiPainTherapeutics
SMi Group is delighted to have Kerrie Brady, Chief Business Officer, Centrexion Therapeutics and Michael Scherz, Founder & CEO, Metys Pharmaceuticals co-chairing the two-day conference.
The co-chairs invite letter mentions:
"It has been a memorable year for the global pain drug development community.
"The first regulatory approvals for CGRP migraine drugs in the US and Europe have ushered in a novel pharmacological strategy for treating and preventing migraine. On the other hand, Nav1.7 inhibitors had significant challenges in their clinical development, as clinical trial results have been less than encouraging.
"The FDA have awarded, for the first time ever, the Breakthrough designation to promising new pain drugs; and the Agency has promised new guidelines that govern the development of novel therapeutics options for the treatment of pain. The US National Institutes of Health have received $500M in additional funding to facilitate the development of new approaches to pain drug development.
"Pain management is a global concern: the European Horizon 2020 'Towards Transatlantic Co-operation in Pain Research' meeting between leading researchers, clinicians, patient groups and government agencies has recommended collaboration priorities for the EU and North America in research on pain and to accelerate access to better and safer pain treatments.
"Clearly, major changes and challenges are afoot in the novel pain therapeutics ecosystem. Will they make a difference in how we develop new analgesic therapies? Will they lead to new treatments for patients?"
The co-chairs for the 19th SMi Group Conference on Pain Therapeutics Conference further explain how the event will discuss new therapies and new clinical trial methodologies will be discussed.
Join the conference for a stimulating series of presentations by leaders in the growing field of novel pain therapeutics.
The co-chairs look forward to welcoming you in London this May.
For further information on the full two-day agenda and speaker line up, visit: http://www.pain-therapeutics.co.uk/PR2
Places can be reserved at http://www.pain-therapeutics.co.uk/PR2
Pain Therapeutics 2019 is proudly sponsored by CHDR, Lotus Clinical Research, MD Biosciences.
There are tailored sponsorship packages available, if you are interested, contact Alia Malick, Director, on +44 (0) 20 827 6168 or email amalick@smi-online.co.uk
For media enquiries, contact Simi Sapal on +44 (0) 20 7827 6000 or ssapal@smi-online.co.uk
Pain Therapeutics 2019
13 – 14 May 2019
Copthorne Tara Hotel, London, UK
http://www.pain-therapeutics.co.uk/PR2
Follow us @SMiPharm
#SMiPainTherapeutics
Contact
SMi Group
Simi Sapal
+44 (0) 20 7827 6000
http://www.pain-therapeutics.co.uk/PR2
Simi Sapal
+44 (0) 20 7827 6000
http://www.pain-therapeutics.co.uk/PR2
Contact
Categories